Rare-disease patients gain faster access to evidence-based treatments
S. 3551 — PROTECT for Rare Act · Filed by Thom Tillis (R-NC) · 1 cosponsor · Introduced Dec 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare, Medicaid, and private health insurance coverage for drugs treating rare diseases (affecting 200,000 or fewer people in the U.S.) by allowing coverage based on peer-reviewed medical literature and clinical guidelines, not just FDA-approved labeling. It also requires health insurers to provide expedited appeals for denials of coverage for such rare-disease drugs. Patients with rare conditions and their doctors benefit by gaining faster access to off-label treatments supported by medical evidence.
Why we flagged it
The bill's core mechanism is to broaden insurance coverage and expedite appeals for drugs treating rare diseases, supported by medical evidence beyond FDA labeling. This is a patient-access and procedural-rights measure, not a deregulation or subsidy.
What the text implies
- Expedited appeals process may create administrative burden on insurers, potentially raising premiums or reducing insurer profitability in the rare-disease segment.
- Reliance on peer-reviewed literature and clinical guidelines as coverage triggers may incentivize pharmaceutical companies to fund or publish studies supporting off-label uses, creating potential conflicts of interest in medical literature.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers of rare-disease drugs; specialty pharmaceutical companies; biotech firms developing orphan drugs